Sector ratings Perspective Therapeutics, Inc.

Stocks

Market Closed - NYSE 04:00:00 18/09/2026 HKT			5-day change	1st Jan Change
2.880 ^USD	+6.67%		-3.68%	+4.73%

08-19	BMO Capital Initiates Perspective Therapeutics at Outperform	MT
08-14	BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6	MT

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Global Valuation
PERSPECTIVE THERAPEUTICS, INC.	308M	-	BBB	-	-
LONZA GROUP AG	45.91B		AAA
IQVIA HOLDINGS INC.	44.25B		AAA
REVOLUTION MEDICINES, INC.	41.99B	-	B	-	-
BEONE MEDICINES AG	39.58B		-
CELLTRION, INC.	31.08B		A
MEDPACE HOLDINGS, INC.	17.21B		BBB
ASCENDIS PHARMA A/S	16.27B	-	-	-	-
EUROFINS SCIENTIFIC SE	14.96B		AA
ICON PUBLIC LIMITED COMPANY	13.42B		AAA
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	13.05B		AA
TEMPUS AI, INC.	12.63B		A		-
BIO-TECHNE CORPORATION	11.34B		AA
PHARMARON BEIJING CO., LTD.	10.83B		AA
ABIVAX	9.1B	-	BBB	-	-
KYMERA THERAPEUTICS, INC.	9.67B	-	BBB	-	-
PROTAGONIST THERAPEUTICS, INC.	9.24B		BB		-
GENSCRIPT BIOTECH CORPORATION	9.08B		AA		-
QIAGEN N.V.	8.87B		AAA
PRAXIS PRECISION MEDICINES, INC.	8.63B	-	B	-	-
Average	18.37B		AA
Weighted average by Cap.			AA